Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Knight Therapeutics Inc.TSX: GUD.TO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of CA$9.41M rose 96.6% year over year, ahead of the +45.4% change in trailing-twelve-month research & development. Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +25.2% a year.

Context

  • Research & development amounted to 6.4% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +96.6% holds above the trailing-twelve-month pace of +45.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$9.41M+2.0% QoQ
Last fiscal yearDec 2025
CA$28.98M+24.4% YoY
LTMMar 2026
CA$33.61M+45.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+96.6%——
1 year+24.4%——
3-year CAGR+25.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
28.98M CAD
Year-over-year change
+24.4%
4-year CAGR
+22.9%

Research & Development vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +45.4% is the 2nd highest of 6, against a peer median of +9.4%.
  • Research & development amounts to 6.6% of revenue for GUD.TO, versus a peer median of 1.5%.
GUD.TO Competitors
Research & Development for GUD.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$33.61M CAD+45.4%+25.2%6.6%
VHI.TOVitalhub Corp.LTM Mar 2026CA$32.77M CAD+92.4%+40.5%27.5%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$13.33M CAD-25.6%-7.0%20.0%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$10.02M CAD+9.4%—3.7%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$4.85M CAD+31.9%-15.1%1.5%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$0 CAD——0.0%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$0 USD-100.0%-39.8%0.0%
TSND.TOTerrAscend Corp.LTM Mar 2026$0 USD——0.0%
Peer median (excluding GUD.TO) —+9.4%-11.0%1.5%

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue243.48M293.56M328.2M371.3M450.09M
Cost of Revenue128.07M155.5M175.55M196.9M299.35M
Gross Profit115.41M138.06M152.65M174.41M150.74M
Gross Margin47.4%47.0%46.5%47.0%33.5%
Research & Development12.69M14.76M17.55M23.3M28.98M
Selling, General & Admin74.38M88.62M83.69M99.35M123.96M
Operating Expenses128.24M155.12M155.54M167.01M152.94M
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
EBITDA42.59M25.26M40.9M64.38M54.37M
EBITDA Margin17.5%8.6%12.5%17.3%12.1%
Operating Income(5.32M)(2.4M)(2.89M)7.4M(2.2M)
Operating Margin-2.2%-0.8%-0.9%2.0%-0.5%
Interest Income7.38M10.63M12.58M10.41M6.21M
Interest Expense3.62M6.6M12.49M9.22M10.42M
Other Income / Expenses19.52M(2.92M)(19.1M)(5.35M)(4.5M)
Income Before Tax6.69M(43.96M)(21.99M)2.05M(6.7M)
Pre-Tax Margin2.7%-15.0%-6.7%0.6%-1.5%
Income Tax Expense(8.99M)(14.07M)(5.15M)(2.28M)(1.33M)
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Net Margin6.4%-10.2%-5.1%1.2%-1.2%
EPS (Basic)0.13(0.26)(0.16)0.04(0.05)
EPS (Diluted)0.13(0.26)(0.16)0.04(0.05)
Weighted Avg Shares124.48M114.89M107.47M101.04M99.57M
Weighted Avg Shares (Diluted)124.52M114.89M107.47M101.44M99.57M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.